Computer-Assisted Drug Design for Neglected Tropical Diseases
We aim to design and develop new chemical entities for the treatment of neglected tropical diseases, such as Dengue, Malaria, Schistosomiasis, Leishmaniasis, Chagas disease, among others, using structure-based drug design (SBDD) and ligand-based drug design (LBDD) strategies for the identification of selective inhibitors of target enzymes, by the combination of experimental and computational approaches.
Development of In Silico Tools for Predicting Pharmacokinetics Properties
Optimization of pharmacokinetics properties (ADME: absorption, distribution, metabolism and excretion) at early stages of drug development has become an essential task to enhance the success rate of new drugs. We are working to overcome or reduce ADME late-stage failures by developing in silico tools or platforms to predict and optimize some of those properties, such as metabolism, Caco-2 cell permeability, blood-brain barrier penetration (BBBP), water solubility, among others, aiming to help the selection of compounds for clinical development.
We aim to apply computer methods to predict adverse effects of chemicals on human health and the environment, as well as to understand the mechanisms underlying the adverse outcome pathway of toxicological endpoints. The application of high-powered computing techniques allows us to manage and detect patterns and interactions in large biological and chemical data sets that helps to select potentially safer compounds to continue on the drug discovery pipeline.